Aurobindo Pharma’s net profit sparkles in Q4FY16

Aurobindo Pharma has declared its Q4FY16 results on May 30. The company’s revenue has increased by 18.49 per cent to Rs 3747 crore in Q4FY16 as compared to same period in previous financial year. Its EBITDA too has risen by 34.48 per cent to Rs 882 crore in Q4FY16 on a yearly basis. Aurobindo Pharma’s EBITDA margin has expanded by 280 basis points to 23.55 per cent in Q4FY16 as compared to same period in previous fiscal year. The company’s net profit also has increased by 39 per cent to Rs 560 crore in Q4FY16 on a yearly basis. Its net profit margin has expanded by 221 basis points to 14.95 per cent in Q4FY16 as compared to previous fiscal year.

On segmental front, Aurobindo Pharma has earned 44 per cent from USA segment, 22 per cent from European Union segment, 20 per cent from API, 9 per cent from ARV and remaining 5 per cent from Emerging markets segment during Q4FY16.

On yearly front, Aurobindo Pharma’s top line has increased by 14.65 per cent to Rs 13896 crore in FY16 as compared to previous financial year. The company’s EBITDA has risen by 25.04 per cent to Rs 3206 crore in FY16 on a yearly basis. Its EBITDA margin has expanded by 189 basis points to 23.07 per cent in FY16 as compared to previous financial year. Aurobindo Pharma’s bottom line has increased by 25.78 per cent to Rs 1982 crore in FY16 on a yearly basis. The company’s net profit margin has expanded by 126 basis points to 14.26 per cent in FY16 as compared to previous fiscal year.

Aurobindo Pharma has entrenched US portfolio of 398 filed ANDAs. The company has 11 ANDAs filed in Q4 FY16 and total 22 ANDAs filed in FY16.  The company has launched 28 products during FY16. Its vertical integration with in-house API stands at approximately 75 per cent of its formulation products. Aurobindo Pharma’s global presence accounts for 87 per cent of sales from international markets, spanning across more than 150 countries.

The share price of Aurobindo Pharma increased by 5.37 per cent on bourses; and is trading at Rs 791.5 on an intraday basis.

Aurobindo Pharma is engaged in producing oral and injectable generic formulations and active pharmaceuticals. The company also manufactures and commercialises active pharmaceutical ingredients (APIs) and generic finished dosages for various markets.